Pneumoconiosis etc. (Workers’ Compensation) (Payment of Claims) (Amendment) (No. 2) Regulations 2026
Wednesday, 28 October 2026
Contributions
Considered in Grand Committee
Moved by
Baroness Sherlock
That the Grand Committee do consider the Pneumoconiosis etc. (Workers’ Compensation) (Payment of Claims) (Amendment) (No. 2) Regulations 2026.
The Minister of State, Department for Work and Pensions (Baroness Sherlock) (Lab)
My Lords, the Committee will also consider the draft Mesothelioma Lump Sum Payments (Conditions and Amounts) (Amendment) (No. 2) Regulations 2026. The schemes we are debating today provide vital support to people who have developed certain dust-related diseases, often caused by occupational exposure to asbestos and other harmful dusts. This includes diseases such as pneumoconiosis and mesothelioma. We all recognise the devastating impact that these diseases can have on individuals and their families, so I am grateful for the opportunity to debate these schemes and the reforms we are making to ensure that they continue to provide effective support. I will begin by providing a brief overview of these two no-fault compensation schemes and what these regulations seek to amend. The Pneumoconiosis etc. (Workers’ Compensation) Act 1979 scheme—henceforth “the 1979 Act scheme”—provides a single lump-sum compensation payment to eligible individuals who suffer from one of the diseases covered by the scheme. This includes diffuse mesothelioma, pneumoconiosis and three other dust-related respiratory diseases. The scheme was designed to compensate people unable to claim damages from former employers that had gone out of business, and who had not brought any civil action against another party for damages. To be entitled to a lump-sum award, claimants must have an industrial injuries disablement benefit award for a disease covered by the 1979 Act scheme—or would have an award but for their percentage disablement. The mesothelioma lump-sum payments scheme—or the “2008 Act scheme”—was introduced to provide compensation to people who contracted diffuse mesothelioma but were unable to claim compensation through the 1979 Act scheme. For example, they may be self-employed or their exposure to asbestos was not due to their work. The 2008 Act scheme provides support to people with diffuse mesothelioma, quickly, at their time of greatest need. Although both schemes aim to provide compensation to sufferers within their lifetime, each scheme also allows for claims by dependants, if the person suffering from the disease sadly dies before they are able to make a claim. This is in recognition of the suffering these diseases can bring to whole families. These regulations make changes to both schemes, the most significant of which relate to awards for dependants and the treatment of claims where a claimant dies before payment can be made. Under the current arrangements, awards payable to dependants are generally lower than those payable to sufferers. These regulations will align the rates payable to dependants with those payable to sufferers under both schemes. That means that dependants will receive compensation calculated using the same rates as eligible sufferers, providing a single payment structure under each scheme. For families already coping with the loss of a loved one, these changes will provide greater financial support at an already difficult time. This is something the House has raised repeatedly with Ministers over the years. Indeed, when I was in opposition, I recall asking the then Ministers about it myself. I am delighted we are able to address this issue at last. The regulations also make provision for circumstances where an individual dies after making a valid claim but before payment is made. In those cases, payment may be made to the claimant’s personal representatives. This will help ensure that compensation can still be paid where an individual has done everything required of them to make a claim but sadly dies before their award can be issued. For the 1979 Act scheme, the regulations also make a number of consequential changes to support these reforms. These include introducing a clear statutory basis for determining the date used to calculate awards and removing payment provisions no longer required following the alignment of award rates. Together, these changes will ensure that the schemes continue to provide meaningful support to those affected by these devastating diseases and their families. I am sure the Committee will want to join me in recognising the continued importance of the compensation offered by the 1979 and 2008 Act schemes. Finally, I am required to confirm that these provisions are compatible with the European Convention on Human Rights, and I am happy to do so. I commend these regulations, which align compensation rates for dependants with those of sufferers and improve the operation of both schemes, to the Grand Committee and ask for its approval to implement them. I beg to move.
Lord Palmer of Childs Hill (LD)
I thank the Minister for introducing these regulations. Be in no doubt that the Liberal Democrats support both instruments, so I hope to be brief. These regulations, as was said, deal with some of the most grievous consequences of working life in this country. Mesothelioma is incurable and usually fatal within a short time of diagnosis. Pneumoconiosis is a legacy of the coal mines, quarries and foundries that once upon a time powered our economy. Those who developed these diseases did nothing wrong except go to work. Those who care for them and those left behind deserve a scheme that treats them fairly, which is what the Minister has helpfully outlined. For that reason, the central change in both instruments is right. At present, as we heard, dependants receive lower awards than the person disabled by the disease. The 1979 Act scheme layers on a complex set of top-ups. A widower or widow has no reason to receive less because their spouse died before a claim was made. Moving to a single-rate structure removes an anomaly that was hard to defend, as the Minister said in her opening remarks. The other welcome change is the provision for payment to personal representatives where a claimant dies after a valid claim but before payment. Given the prognosis for mesothelioma, the scenario is far from hypothetical. It is cruel that a family could lose an award simply because the administrative process was slower than the disease. Even so, I should like to put some questions to the Minister. First, the Government expect dependants to be “better off overall”. Can the Minister please confirm whether anyone will be worse off? The additional dependant top-up, the minimum payment and the tuberculosis-related top-up are all being removed. Has the department modelled the individual cases most likely to lose out? If so, what is the transitional protection? Secondly, these rules apply only when entitlement first arises on or after 31 October. Families whose entitlement arose just before that date will receive less, for some reason, for the same loss. I understand the legal logic, but what is the Government’s response to those families who no doubt will feel unhappy about that? Thirdly, on the clearer relevant date rules, I welcome the reduction in disputes. Can the Minister say how claimants will be told which date applies to them and whether the department will publish guidance before 31 October? Fourthly, the instruments replace references to assessment bodies with medical practitioners appointed by the Secretary of State. What assurance can the Minister give us about capacity and waiting times for assessment? Delay is the enemy of anyone with a terminal diagnosis. Fifthly, on probate administration and confirmation documents, how will the department help bereaved families, who may be struggling to obtain them quickly? With those questions, the answers to which I think will add to the debate today, I am pleased from these Benches to support the regulations.
Baroness Stedman-Scott (Con)
My Lords, I thank the Minister for introducing these two instruments and setting out their purpose. I confirm at the outset that we on these Benches welcome these changes and are pleased to support both instruments. Mesothelioma, pneumoconiosis and other dust-related diseases cause immense suffering to workers and their families, often emerging decades after the original exposure to asbestos or other harmful substances. Many of those affected spent their lives working in industries such as mining, shipbuilding and construction, contributing enormously to our country’s prosperity, only to face devastating illness later in life. It is important to remember that the effects of these conditions extend far beyond those diagnosed. Families are often left to contend not only with the emotional toll of serious illness and bereavement but with substantial financial pressures. The compensation schemes established under the 1979 and 2008 Acts therefore provide an essential safety net, particularly where a former employer has ceased trading or those affected cannot obtain compensation through other means. The central change introduced by these two instruments is welcome. It is right that dependants should receive compensation calculated at the same rates as sufferers themselves. A family’s need for support does not diminish because their loved one died before making a claim. I also welcome the provisions enabling payments to be made through a claimant’s personal representatives, where an individual dies after submitting a valid claim but before receiving compensation. I want briefly to take this opportunity to recognise the tireless work of charities, campaigners and victims’ organisations that have advocated for these changes over many years, including Mesothelioma UK and the Asbestos Victims Support Group Forum UK. We support the principles underpinning both instruments, but I should be grateful if the Minister can provide further clarification on their practical implementation. First, on the administration of payments following a claimant’s death, the regulations provide for compensation to be paid to personal representatives once the necessary evidence of probate, letters of administration or confirmation as executor have been supplied. Although those requirements are understandable, obtaining the necessary documentation can be a lengthy process, particularly for families dealing with bereavement. Can the Minister therefore explain what steps the department is taking to ensure that these requirements do not cause unnecessary delays. Will the Government introduce a target processing time for payment once the relevant documentation has been received? What guidance and practical assistance will be provided to bereaved families? Secondly, I turn to the removal of existing supplementary payments under the pneumoconiosis scheme. The regulations remove a number of existing top-up provisions, including the provision relating to sufferers whose pneumoconiosis is accompanied by tuberculosis. The Government have suggested that the higher basic awards mean that claimants will benefit overall from the new arrangements. Can the Minister nevertheless give a categorical assurance that no individual claimant will receive a lower award as a result of these changes, including anyone who had previously qualified for the tuberculosis-related payment. If that assurance cannot be given, how many claimants does the department estimate could receive less? What is the maximum potential reduction and what transitional protection has been considered? Thirdly, I turn to the transitional arrangements. Both instruments are intended to come into force on 31 October but they use different tests to determine who benefits from the new provisions. Under the 1979 Act scheme, the amendments apply where a person first fulfils the conditions of entitlement on or after that date. Under the 2008 Act scheme, the increased dependant rate applies where the sufferer dies on or after that date. Can the Minister explain the reason for using these different tests? How will the department treat cases in which a person fulfils the entitlement conditions or dies shortly before 31 October but the claim has not been determined by that date? In particular, what consideration has been given to families who may receive a substantially lower payment solely because the relevant event occurred shortly before the commencement date? Fourthly, I turn to the speed of payments and awareness of schemes. These schemes are intended, wherever possible, to provide compensation to sufferers during their own lifetimes. Given the often rapid progression of these diseases following diagnosis, it is essential that applications are processed without unnecessary delay. Can the Minister tell the Committee the current average and median processing times under both schemes? How many claimants have died after submitting a valid claim but before receiving payment, in each of the past five years?
More broadly, improving entitlement is valuable only if those eligible are aware of the support available. What further steps will the Government take to work with clinicians, specialist nurses, charities and other support organisations to ensure that sufferers and their families are aware of these changes and can access compensation properly?
Finally, I would welcome some clarification on the longer-term future of these schemes. When the House considered the annual uprating regulations earlier this year, the Minister confirmed that 3,150 awards had been made under the two schemes in 2024-25, with a total expenditure of £51.6 million. Given the long latency periods associated with asbestos-related diseases, the human and financial consequences of historical exposure will continue to be felt for many years. The Minister therefore outlined the Government’s projections for claimant numbers and expenditure over the next five to 10 years, including the additional expenditure expected to arise from these changes.
I also welcome the continued practice of uprating these payments annually, notwithstanding the absence of a statutory obligation to do so. Can the Minister confirm that the Government intend to maintain that commitment in future years?
These are fair and important reforms; they reflect the principle that families affected by these terrible diseases should not be disadvantaged simply because the sufferer dies before a claim can be made or payment received. Without any doubt, we support both these instruments. If it helps the Minister, I would be happy if she wants to write on some of those questions, because there were quite a few.
Baroness Sherlock (Lab)
My Lords, I am very grateful to the noble Lord, Lord Palmer, and the noble Baroness, Lady Stedman-Scott, for those responses, and I thank them for their clear support for these changes. I had every confidence that the Committee would appreciate the alignment of rates for dependants with those for sufferers. As the noble Lord, Lord Palmer, pointed out and as was helpful to hear in the discussion, these diseases are products of our industrial heritage. The people suffering from them just went to work. That was a very poignant way to put it: they had simply gone to work and done the right thing; then, from no fault of their own, they ended up suffering these terrible diseases decades later. The least we can do is to support people by giving them this compensation in the late years of their life. With these changes, that can carry on; sometimes these diseases progress horrifically quickly and the claims cannot be processed in time. At least now the sufferers will know that their dependants will get the money due to them. There were a couple of other questions. If the noble Baroness, Lady Stedman-Scott, does not mind, as she was asking for quite a lot of specific detail about projections, I will write to her on those because it would be too much to go through them now. There were two questions I want specifically to address. One was whether anyone will lose out. It is not possible to rule out that a small number of people may receive less than they otherwise would have, as a result of removing certain supplementary provisions. But the department expects the number affected to be very small. Taken together with the annual uprating and the wider package of reforms, the overall effect is expected to be positive for claimants and their dependants. At the moment, the gap between sufferers and dependants can be £7,000; it is that specific. If I have any more precise information about modelling, I will write to noble Lords. Both noble Lords raised clearance times and why people are waiting for longer processing times, both for claims and related documentation. I reassure the Committee that reducing processing times is a clear priority for my department. Journey times vary depending on the complexity of individual cases and, in some instances, additional checks are needed to make sure that the entitlement criteria are properly met. That can take longer, but it is important to get the decisions right. We are working hard to reduce backlogs and speed up claims, including by modernising processes that have been around since before the pandemic and expanding the use, where appropriate, of paper-based or video assessments for IIDB. For certain prescribed conditions, including diffuse mesothelioma and seven other specified conditions, disablement is automatically assessed at 100%, which means that a medical assessment may not be necessary. That would help ensure that those with the most serious conditions receive faster decisions. I reassure noble Lords that we are working hard on that. There is no doubt that there has been an increase in processing times for mesothelioma claims, but officials are working hard to address that and to make sure that customers receive their awards as quickly as possible. I want to reassure the Committee that the department fully understands the implication of that and the impact on families and is working through understanding the reasons for that. I think those are the main questions that were asked, but I will go through Hansard and if I have missed anything else, I will write to noble Lords. I thank noble Lords for their continued support for these schemes. The Government are committed to sharing the importance of them. I commend to the Committee the importance of these reforms, which align compensation payable to dependants with that payable to sufferers under both schemes, and the fact that they will also allow provision for payment to personal representatives. The schemes will continue to support people affected by some of the most serious occupational diseases and, where appropriate, their dependants. The reforms before the Committee were prompted by an independent legal review of the schemes, and they provide an opportunity to address a number of long-standing issues relating to their operation. Taken together, these changes will align awards for dependants and sufferers. They will provide greater clarity. I say to the noble Baroness, Lady Stedman-Scott, that I share her position and add my thanks to many charities who have worked in this area. As regards communications, we published a press notice on the reforms, endorsed by the Asbestos Victims Support Group Forum, to raise awareness of the changes, and we will always keep an eye out for ways to make sure people know what is there. As for an estimation of awards, I am reflecting further. The dependant rate increase is estimated to cost between £2 million and £6 million annually and the relevant date changes are expected to cost under £1 million. Both were funded through the 2025 spending review. On numbers, in 2025-26 there were 220 awards to dependants under the 1979 Act scheme, which is about 10% of the total caseload, with £2.5 million paid out. On the 2008 Act scheme there were around 70 awards to dependants in 2025-26, representing about 11% of the caseload, with £700,000 paid out to dependants. Going forward, the great news is that dependants under both schemes will benefit from equal payments to the sufferer. That is probably most of the points, but as I said, if there is anything else, I will check the record and write to noble Lords. I commend these amendments to both schemes to the Committee and ask approval to implement them. I beg to move.
Motion agreed.
← Previous
Arrangement of Business
Next →
Mesothelioma Lump Sum Payments (Conditions and Amounts) (Amendment) (No. 2) Regulations 2026
Source: UK Parliament Hansard API. Debate ID: 5427325.